Caspofungin (CAS) is approved for second line management of proven or probable invasive aspergillosis at a dose of 50 mg once daily (QD). Preclinical and limited clinical data support the concept of dose-dependent antifungal efficacy of CAS with preservation of its favourable safety profile. Little is known, however, about the pharmacokinetics of higher doses of CAS in patients.